bakertilly
MOHAMED HILAL & WAHID ABDEL GHAFFAR

Degla view building -Ring road,
Katameya,Cairo, Egypt

C61, Plot# 11, 10th Sector,
Zahraa El Maadi, Cairo.

87 Ramsis Street, Cairo.
Egypt

T: +2 2725 10 04
T: +2 2725 10 08
T: +2 2725 10 09

T: +2 2310 10 31,32,33,34,35

T: +2 2574 48 10
T: +2 2577 07 85

info@bakertillyeg.com
www.bakertillyeg.com

Independent Limited Assurance Report on the Board of Directors report of GlaxoSmithKline (S.A.E) on Compliance with the Corporate Governance Guidelines issued by the Financial Regulatory Authority Board of Directors Resolution No. (84) of July 26, 2016

To the Board of Directors of GlaxoSmithKline (S.A.E).

Introduction

We have performed an independent limited assurance engagement on the preparation and presentation of the attached report on compliance with corporate governance rules ("the Report") prepared by GlaxoSmithKline (S.A.E) Board of Directors ("the Board") for the year ended December 31, 2025, in accordance with the Indicative Report Format ("IRF") issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018.

Management's responsibility

The Board of Directors of the Company is responsible for the preparation and presentation of the Report and for ensuring compliance with the Indicative Report Format ("IRF") issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018, and the Egyptian Corporate Governance code issued by the Financial Regulatory Authority's board of directors' resolution No (84) dated July 26, 2016. The Board's responsibility includes the identification, disclosure and explanation of instances of non-compliance thereto. The Board is also responsible for the design, implementation and maintenance of adequate systems and processes relevant for the preparation of the Report.

Our responsibility

Our responsibility is to express a limited assurance conclusion on whether any matters has come to our attention that cause us to believe that the attached Board of Directors report has not been prepared and presented, in all material respects, in accordance with the Indicative Report Format ("IRF") issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018, based on the limited assurance procedures we performed.

We conducted our work in accordance with Egyptian Standard on Assurance Engagements no. (3000) Assurance Engagements other than Audits or Reviews of Historical Financial Information. This standard requires that we comply with the applicable professional standards including independence requirements, and that we plan and perform our work to obtain limited assurance whether any matters have come to our attention that cause us to believe that the Board of Directors' report on compliance with corporate governance rules has not been prepared, in all material respects, in accordance with the Indicative Report Format ("IRF") issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018.

The extent of the procedures performed for evidence gathering in a limited assurance engagement are less than those performed for a reasonable assurance engagement, and therefore a lower level of assurance is provided.

The procedures performed were based on our own judgement, evidences were primarily obtained through enquiries of management, observations of certain procedures performed by management, reviewing selection of supporting documentations and, where applicable, matching with the Company's records.

Performing the above procedures included the following:

- Enquiries of management to gain an understanding of management's processes, to prepare and present the Report in accordance with the issued guidance, in addition to the procedures performed by management to ensure compliance with corporate governance requirements and management processes to evaluate compliance with issued guidance.
- Matching the Report's structure and content as prepared and presented by the Board of Directors with the indicative report format included in the IRF issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018.
- Where applicable, matching with the information included in the Report with the Company's records and supporting documentation.
- Review a sample of documentation supporting measurable information, where necessary, in the board of directors' report.

According to paragraph 49(d) of ESAE (3000), our procedures were limited to measurable matters that are capable of being assessed reliably. Such procedures did not cover non-quantitative matters nor the effectiveness, validity or completeness of matters such as management's procedures and processes to comply with Corporate Governance. It also does not cover evaluation of the performance of the Board of Directors', its committees' or the management, nor the evaluation of instances of non- compliance, violations or rulings. Our procedures also did not cover evaluating the effectiveness of the Company's internal control systems, compliance and the effectiveness of its corporate governance. This report is solely prepared for the purpose of fulfilling our responsibility under the requirements of article (40) of the Egyptian Listing Rules and not for any other purpose. Accordingly, this report cannot be used except for the purpose it was prepared for.

Inherent limitations

Procedures performed by entities to comply with administrative and legal rules, in most cases, rely on the individuals performing them, their understanding of the procedures' objectives, and their evaluation of the effectiveness of performed procedures. In some instances, they cannot be evidenced. The absence of a significant body of established practice on which to draw allows for selection of different but acceptable compliance procedures that are not comparable.
Non-financial information, such as those included in the Report, are subject to more inherent limitations than financial information, given the more qualitative characteristics of the Board of Directors' report on the compliance with corporate governance and the methods used for preparing the Report.

bakertilly
MOHAMED HILAL & WAHID ABDEL GHAFFAR

Conclusion

Based on the limited assurance procedures performed, as described above, nothing has come to our attention that would lead us to believe that the attached Board of Directors' report of GlaxoSmithKline (S.A.E) on compliance with corporate governance rules for the year ended December 31, 2025 has not been prepared and presented in accordance with the Indicative Report Format ("IRF") issued by the Egyptian Stock Exchange as addressed in a letter to the Chairman of the Board of the Company dated December 25, 2018.

Cairo, March 12, 2026

Mohamed Hossam Hilal, CPA, ESAA

R.A.A no. 30440
Baker Tilly MOHAMED HILAL & WAHID ABDEL GHAFFAR

Corporate Governance Report

GlaxoSmithKline S.A.E.

For the financial year ending 31\12\2025

Information about the Company:

Company Name	GlaxoSmithKline S.A.E		
Company Purpose:	1. Production of pharmaceutical chemicals approved by the Ministry of Health, using the latest preparation methods for both the local and international markets. 2. Production of pharmaceutical preparations in various forms, applying the GMP system in accordance with what is approved by the specialized scientific committees at the Ministry of Health. 3. Allowing other factories and companies, whether global or local, to operate at the company in order to achieve the best use of the available surplus production capacity. 4. Production of cosmetics (provided the production is under a global brand name, ensuring the existence of an external export market, and that the manufacturing process is integrated in terms of internal manufacturing of the majority of production supplies, packaging, and using machinery and equipment in line with global advancements in cosmetic manufacturing technology). 5. Outsourced manufacturing. 6. Filling and packaging of pharmaceutical products (bulk). 7. Registration of medicines and products (pharmaceutical, biological, and dietary supplements) that are either locally produced or imported, and registering them with all relevant authorities, including but not limited to the Ministry of Health and the Egyptian Drug Authority.		
Company's Term	Fifty years	Date of Listing on the Stock Exchange	23\10\1985
Applicable Law	Law No. 43 of 1974, as amended by the current Law No. 72 of 2017	Nominal Value of the Share	10 Egyptian Pounds
Most Recent Authorized Capital	**One billion Egyptian pounds**	Most Recent Issued Capital	**835,142,000 Egyptian pounds**
Most Recent Paid-up Capital	835,142,000 Egyptian pounds	Commercial Register Number and Date	208407 14\1\1981

Contact Info	Omar Sameh Shukri		
Headquarter Address	Boomerang Administrative Building, Sector 1, No. 46, New Cairo, Fifth Settlement		
Phone Number	26185000	Fax	26185001
Website	http://www.gsk.com/en-gb/contact-us/worldwide/egypt/		
E-mail	EG.Investor-Relation@GSK.com		

General Assembly of Shareholders

1. Every shareholder has the right to attend the General Assembly of Shareholders in person or by proxy. A shareholder may not represent more than 10% of the total nominal shares comprising the company's capital through a proxy, and may not represent more than 20% of the shares present at the meeting.
2. A shareholder who is not a member of the Board of Directors may not appoint a member of the Board of Directors as a proxy to attend the General Assembly. To be valid, the proxy must be documented in writing, and the proxy must be a shareholder.
3. Any shareholder wishing to submit questions, inquiries, or suggestions must send them in writing to the company at its headquarters in the Boomerang Administrative Building, Fifth Settlement, New Cairo, either by hand against a receipt or by registered mail, at least three days before the General Assembly meeting, and they must be related to the topics included in the agenda.
4. Shareholders wishing to attend the General Assembly must provide proof that they have deposited an official statement from a Securities Registration Management Company at the company's centre at least three days prior to the General Assembly. The statement must be accompanied by a certificate from the Securities Registration Management Company confirming that the shareholding is frozen until the conclusion of the meeting.
5. Any transfer of share ownership is suspended from the date of the invitation to the General Assembly until the conclusion of the General Assembly meeting.

Ownership Structure

Shareholders holding 5% or more of the company's shares	Beneficial Owner	Number of Shares as of Financial Statements Date	Percentage (%)
Glaxo Group Limited	Glaxo Group Limited	76,161,378	91.20%
Qatar National Bank	Qatar National Bank	4,918,550	5.89%
Total		81,079,928	97.09%

Board of Directors

The Board of Directors of the company is responsible for the following tasks:

- Approval of mechanisms and systems that ensure all employees of the company comply with the laws, codes, and internal policies of the company.
- Approval of work plans and monitoring the performance of the executive management.
- Determining the authorities that are delegated to members or committees, and following up on the results of exercising those delegated authorities.
- Approval of preventive measures, tools, and mechanisms to secure the flow of information and ensure the accuracy and integrity of data within the company.
- Supervising the disclosure process and communication channels, ensuring the integrity of the financial and accounting reports issued by the company, and ensuring the independence of both the internal audit and compliance functions within the company.
- Appointing a board secretary with the necessary competence and understanding of all company operations.

GSK
Glaxosmithkline S. A. E
جلاكسو سميثكلاين ش. م. م
القاهرة الجديدة

Board of Directors' Structure:

The structure of the company's Board of Directors for the first and second quarters of 2025 was as follows:

Structure of the Board of Directors before Amendment:

No.	Member Name	Member Title (Executive/Non-Executive/Independent)	Number of Shares Owned	Date of Joining	Representing
1	Ahmed Abdel Hamid Fahmy Khattab	Non-Executive Chairman	--	18/04/2020	Glaxo Group Limited
2	Hassan Mahmoud Hassan Mahfouz Fahmy	Managing Director (Executive)	--	09/10/2023	Glaxo Group Limited
3	Vikas Jain	Executive	--	10/09/2023	Glaxo Group Limited
4	Leila Daniel Shaker Boulos	Executive	--	18/08/2021	Glaxo Group Limited
5	Mohamed Ali Abdel Azim Ahmed	Executive	--	21/02/2022	Glaxo Group Limited
6	Sherine Al-Ansari	Non-Executive	--	14/06/2007	Qatar National Bank (QNB)
7	Omar Sameh Shoukry	Executive	--	10/09/2023	Glaxo Group Limited
8	Mounir Ghabour Hanna	Independent Member	--	08/01/1981	
9	Omnia Saad Abdelrahman Qalaj	Independent Member	--	18/08/2021	----

The structure of the company's Board of Directors for the third and fourth quarters of 2025 was as follows:

Structure of the Board of Directors After Amendment:

No.	Member Name	Member Title (Executive/Non-Executive/Independent)	Number of Shares Owned	Date of Joining	Representing
1	Samer Taalat	Executive Chairman	--	31/12/2025	Glaxo Group Limited
2	Heba Elmorshdy	Executive	--	24/12/2025	Glaxo Group Limited
3	Leila Daniel Shaker Boulos	Executive	--	18/08/2021	Glaxo Group Limited
4	Mohamed Ali Abdel Azim Ahmed	Executive	--	21/02/2022	Glaxo Group Limited

GlaxoSmithKline S. A. E

جلاكسو سميثكلاين ش. م. م

5	Sherine Al-Ansari	Non-Executive	--	14/06/2007	Qatar National Bank (QNB)
6	Omar Sameh Shoukry	Executive	--	10/09/2023	Glaxo Group Limited
7	Mounir Ghabour Hanna	Independent Member	--	08/01/1981	
8	Omnia Saad Abdelrahman Qalaj	Independent Member	--	18/08/2021	----

Chairman of the Board

The company outlines the extent to which the Chairman fulfills his various duties, including the following:

- Issuing the invitation for Board meetings, setting the agenda, and managing the sessions.
- Calling the ordinary and extraordinary General Assemblies to discuss the agenda presented by the Board.
- Ensuring the availability of sufficient and accurate information in a timely manner for the Board members and shareholders.
- Ensuring decisions are made based on sound judgment and a comprehensive understanding of the topics, with the necessary mechanisms in place to ensure the effective and timely execution of those decisions.
- Receiving reports and recommendations from all committees and presenting them to the Board regularly for appropriate action.
- Ensuring each Board member conducts a self-assessment to evaluate their compliance with their duties.
- Ensuring the Board carries out its tasks effectively, in the best interest of the company, while avoiding any conflicts of interest.

Managing Director

The company outlines the extent to which the Managing Director fulfills his various duties, including:

- Leading the company's executive operations, overseeing the workflow across departments, and taking the necessary decisions to maintain operational efficiency and achieve company objectives.
- Implementing the company's strategy and annual plan as approved by the Board of Directors.
- Managing daily operations and supervising all departments and divisions, monitoring performance across all activities, making decisions to maintain workflow and accomplish goals, and working to enhance customer satisfaction.
- Ensuring the implementation of all policies, regulations, and internal systems approved by the Board.
- Proposing agenda items for Board meetings in consultation with the Chairman.
- Ensuring the preparation of periodic financial and non-financial reports on the company's results and performance evaluation, including the corporate governance report, and reviewing all responses to auditors' inquiries before these reports are finalized.

The Board of Directors is composed of members with recognized competence and expertise in the company's field of activity.

Board Secretary

The Board Secretary serves as a liaison between the Board members and the company's senior management as follows:

- Preparing and organizing Board and committee meetings, assisting the Chairman in setting the meeting agenda, and preparing and distributing the relevant information, data, and materials to members well in advance of the meetings.
- Assisting the Chairman in organizing General Assembly meetings for shareholders.
- Following up on the issuance and execution of Board decisions.
- Maintaining and documenting all matters related to Board resolutions and agenda items, ensuring the Board receives critical information in a timely manner.
- Coordinating with all Board committees to ensure effective communication between these committees and the Board.

Board of Directors Committees

Committee Structure

The company presents in the table below the structure of the committees stemming from its Board of Directors and senior management, along with a clarification of any cases where the responsibilities of certain committees have been merged.

No.	Member Name	Committee Name					Membership Type (Executive\ Non-Executive)	Position in the Committee	Date of Joining
		Audit	Nomination	Remuneration	Risk	Governance			
1	Rizk Wadeed Rizkallah	√					Independent	Chairperson	11/10/2011
3	Yasser Rizk	√					Independent	Member	11/10/2011
2	Ibrahim El-Meligy	√					Independent	Member	11/10/2011
4	Omnia Saad Abdelrahman Qelej	√					Independent	Member	26/05/2021
1	Samer Taalat				√		Executive	Chairperson	1/05/2020
2	Ahmed Sami				√		Senior Management	Member	17/08/2010
3	Ehab Abdel Latif				√		Senior Management	Member	10/02/2011
4	Sara Mostafa				√		Senior Management	Member	25/02/2020
5	Soliman Abdeldayem				√			Member	

6	Mohamed El-Ga'ar				√		Senior Management	Member	10/02/2019
7	Omar Shokry				√		Executive	Member	
8	Samer Talaat				√		Senior Management	Member	01/05/2020
9	Yasser El-Makhzangy				√		Senior Management	Member	09/06/2019
10	Walied Habib				√		Senior Management	Member	
11	Walid Ismail				√		Senior Management	Member	
12	Dina Gamil				√		Senior Management	Member	
13	Hassan Al-Sawi				√		Senior Management	Member	
14	Soha Abbas				√		Senior Management	Member	
15	Mai Gamal				√		Senior Management	Member	
16	Mohab Al-Tabalawy				√		Senior Management	Member	
17	Bavly Bassily				√		Senior Management	Member	
18	Ahmed Ashraf				√		Senior Management	Member	

Conduct of Board and Committee Meetings

The company presents the conduct of meetings of the Board of Directors and its committees, including the number of meetings held and the names of the members who attended, in the following format:

Attendance Table for Board Members and Senior Management at Board and Committee Meetings:

No.	Member Name	Board of Directors	Audit Committee	Risk Committee
1	Ahmed Abdelhamid Fahmy Khattab	5/5		
2	Hassan Mahmoud Hassan Mahmoud Fahmy	5/5		6/6
3	Heba El-Morshedy	1/5		3/6
4	Vikas Jain	1/5		1/6
5	Omar Sameh Shokry	4/5		6/6
6	Laila Daniel Shaker Boulos	5/5		
7	Mohamed Ali Abdelazim Ahmed	4/5		
8	Shereen Al-Ansary	4/5		
9	Mounir Ghabbour Hanna	0/5		
10	Omnia Saad Abdelrahman Qallig	3/5		
11	Adeel Kassimov			5/6
12	Ahmed Sami			6/6
13	Ehab Abdel-Latif			1/6
14	Sara Mostafa			6/6
15	Mohamed El-Gaaar			6/6
16	Yasser El-Makhzangy			6/6
17	Samer Talaat			2/6
18	Rizk Wadie Rizkallah			
19	Ibrahim El-Meligy			
20	Hassan El-Sawy			2/6
21	Mai Gamal			2/6
22	Walid Habib			5/6
23	Walid Ismail			6/6
24	Gamal Heba			1/6
25	Bavly Basily			4/6
26	Mohamed El-Attar			1/6
27	Mohab El-Tablawy			2/6
28	Hossam Mostafa			1/6
29	Soliman Abdeldayem			5/6
30	Dina Gameel			6/6
31	Laila Bazy			1/6
32	Walid Anany			1/6
33	Soha Abbas			4/6
34	Ahmed Ashraf			1/6
35	Mohamed El-Tahawy			1/6
36	Shady Waseem			1/6

Glaxosmithkline S. A. E

Audit Committee

The internal audit committee is composed of non-executive and independent members. The company discloses the various tasks performed by the audit committee, which include:

- Reviewing the financial statements before they are presented to the Board of Directors and providing their opinion and recommendations on them.
- Reviewing the accounting policies used and providing their opinion and recommendations on them.
- Recommending to the Board of Directors the appointment of one or more auditors for the company, as well as their qualifications, competence, and independence. The decision on their appointment and determination of their fees is within the authority of the company's General Assembly.
- Reviewing the audit plan of the auditor and providing feedback on it.
- Reviewing the auditor's comments and recommendations on the financial statements and other matters in the management letter from the auditor and following up on the actions taken in response.
- Ensuring that the company complies with applicable systems, regulations, and accounting standards based on reports submitted to it by the Compliance Department or other relevant departments.
- Reviewing any observations or violations from regulatory authorities and following up on the actions taken in response.
- Inviting the company's auditor, the head of the internal audit department, or any relevant person from inside or outside the company to attend its meetings whenever necessary.
- Executing and following up on any other tasks assigned to it by the Board of Directors.

Structure of the Audit Committee

The structure of the company's audit committee remained unchanged during the year

No.	Member Name	Membership Type (Executive\Non-Executive)	Position in the Committee	Date of Joining
1	Rizk Wadeed Rizkallah	Independent	Chairperson	11/10/2011
2	Ibrahim El-Meligy	Independent	Member	11/10/2011
3	Omnia Saad Abdelrahman Qalag	Independent	Member	26/5/2021

Nomination Committee

The Corporate Secretariat Department of the parent company is responsible for the Nomination Committee as follows:

- Conducting regular and ongoing reviews of the required skills for board membership and senior management positions, and preparing a statement of the qualifications needed in line with the implementation of the succession plan.

- Defining the responsibilities of the board members, both executive and non-executive, as well as independent members, and developing job descriptions for the company's senior executive leadership.
- Continuously verifying the independence of the independent board members and ensuring there is no conflict of interest, especially if a member holds a position on the board of another company.

Remuneration Committee

The company does not have a remuneration committee that is formed under the Board of Directors.

Risk Committee

The company has a committee for evaluating and managing risks and ensuring compliance with policies. This committee is responsible for the following tasks during the year:

- Establishing the necessary executive frameworks, procedures, and rules to address all types of risks that the company may face, including strategic risks, operational risks, market risks, credit risks, reputational risks, information systems risks, data protection risks, and any other risks that may impact the company's operations and sustainability.
- Assisting management in identifying and assessing the level of risk the company is willing to accept, and ensuring that the company does not exceed this acceptable risk threshold.
- Supervising and verifying the effectiveness of the company's risk management.
- Preparing periodic reports on the outcomes of its work and providing recommendations for necessary actions, as well as following up on the implementation of these recommendations.

Governance Committee

The company does not have a governance committee, and the executive management is responsible for the following tasks:

- Conducting regular evaluations of the company's governance system and developing guidelines, charters, and internal policies on how to apply governance rules within the company.
- Preparing an annual report on the company's compliance with corporate governance rules, along with establishing appropriate procedures to ensure full implementation of those rules.
- Reviewing the company's annual report and the Board of Directors' report, particularly with respect to disclosure items and other governance-related matters.
- Reviewing observations from regulatory authorities on the implementation of governance within the company, taking them into account, and following up on the actions taken in response.

Control Environment

Internal Control System

Various departments within the company, in cooperation with the Compliance Officer, work to ensure the efficiency and adequacy of the internal control system. This system is based on a set of policies, procedures, guidelines, and regulations prepared by the relevant departments and approved by the Board of Directors to achieve the following objectives:

- Complete separation of responsibilities and authorities for all employees within the company.
- Ensuring the accuracy and quality of information, so that both the company and external parties have access to correct and precise data about the company.
- Protecting the company's physical assets from risks they may face and ensuring proper documentation and registration of these assets in the company's records.
- Enhancing the operational efficiency of the company, achieving its objectives with minimal costs while maintaining quality.
- Ensuring the application of corporate governance rules through the accurate implementation of various governance instructions and regulations.

Additionally, the system defines responsibilities and ensures a clear separation of duties, which is taken into consideration when preparing the company's organizational structure.

Internal Audit Management

The internal audit functions are managed centrally by the parent company, which performs the following tasks:

- Evaluating the effectiveness of the company's internal control system.
- Assessing the compliance of all company departments in executing their tasks according to established procedures and policies, ensuring no conflict with the responsibilities of other relevant departments.
- Evaluating the efficiency of the implemented procedures and policies, and ensuring their alignment with the evolving business and market developments.
- Following up on the corrective actions taken in response to the observations highlighted in internal and external audit reports, as well as those from regulatory authorities.

Risk Management

The Risk Committee and Compliance Policies are generally responsible for risk management in a manner consistent with the nature of the company's activities, its size, and the market in which it operates. The company outlines the responsibilities of risk management during the year, which include:

- Analyzing the risks that the company may face and conducting this analysis accurately and in a timely manner.
- Ensuring the full implementation of the internal control framework.
- Assessing changes in the legal or regulatory environment and/or industry practices and providing recommendations when the company's practices are either inconsistent with or could be improved upon in relation to these changes.
- Ensuring that relevant employees complete mandatory and expected training requirements within the specified time.
- Reviewing audit, inspection, compliance, and internal investigation reports, as appropriate, to ensure the implementation of corrective actions and communicating relevant aspects.
- Implementing and overseeing the results of management monitoring activities and independent administrative oversight activities to ensure the company documents and implements appropriate monitoring programs, with escalation processes and problem resolution.
- Ensuring that all significant meeting results and actions (such as those related to violations, corrective actions, training, etc.) are properly documented, communicated, and escalated when necessary.

- Ensuring that no illegal or unethical practices occur within the company, including money laundering, corruption, and terrorism financing, and addressing reports of such practices in a fair, confidential manner. These reports should be presented to the Audit Committee, with follow-up on actions taken, ensuring the protection of whistleblowers.

Governance Management

The executive management is responsible for the following tasks concerning governance management:

- Monitoring the availability of the principles and key elements that help in developing and improving the company's performance, contributing to the achievement of the strategic objectives set by the Board of Directors.
- Monitoring the implementation of the principles of disclosure, transparency, and governance culture across all company operations and activities.
- Monitoring the application of the policy to avoid conflicts of interest for all company employees.

Financial Auditors

Auditor's Name	Mohamed Hossam Helal (Baker Tilly "Mohamed Helal & Waheed Abdel Ghafar Office")		
Date of Appointment	**24/09/2023**		
Registration Number	**132**	**Registration Date**	**28/05/2013**

The General Assembly of the company's shareholders appoints the auditor based on a nomination from the parent company, which is then presented to the Board of Directors for approval and subsequently to the General Assembly of the company. Mr. Mohamed Hossam Helal (Baker Tilly "**Mohamed Helal & Waheed Abdel Ghafar Office**") was appointed to replace Mr. Wafiq Al-Farid Hanna (Wafiq, Rami & Partners - Deloitte), according to the Board of Directors' decision dated 27 September 2023, which was approved by the General Assembly meeting held on 14 December 2023. His fees were also determined, as he meets the requirements set forth in the Accounting and Auditing Profession Law and is listed as an auditor in the records of the General Authority for Financial Supervision, ensuring his independence in performing his duties.

The auditor submits quarterly reports on the financial statements to the Board of Directors and provides an annual report on the financial statement audit to the members of the company's General Assembly.

Mr. Mohamed Hossam Helal (Baker Tilly "**Mohamed Helal & Waheed Abdel Ghafar Office**") was reappointed as the company's auditor for the fiscal year ending on 31 December 2025, with his fees determined by the unanimous approval of the General Assembly in its meeting held on 28 May 2025.

Disclosure and Transparency

Material Information and Financial and Non-Financial Disclosure

The company adheres to the disclosure requirements set by the General Authority for Financial Supervision and the Egyptian Stock Exchange. The company aims to achieve transparency by disclosing both financial and non-financial information, as well as material events, and publishing them through electronic disclosure on the Egyptian Stock Exchange. The annual and periodic financial statements, along with the auditor's reports on audits and periodic reviews, as well as the Board of Directors' report, are also published on the Stock Exchange website in addition to the company's website, which is regularly updated. The following information is disclosed:

- Submitting decisions of the General Assembly (ordinary and extraordinary) to the Authority and the Exchange immediately after the meeting in compliance with legal timelines. Decisions relevant to shareholders are also published on the company's website.
- Submitting a summary of the Board of Directors' decisions containing material events to the Authority and the Exchange immediately after the meeting, in compliance with legal timelines.
- Announcing cash distributions as soon as they are approved.
- Regular disclosure of the shareholder structure, including those who own 5% or more.
- Regular disclosure of any material events that affect the company's financial position.
- Regular disclosure of transactions with related parties, compensation contracts, and treasury shares.

Investor Relations

Contact Name	**Omar Sameh Shokry**	**Investor Relations Manager**	01008825558
Head Office Address	Boomerang Administrative Building, Sector 1, No. 46, Fifth Settlement, New Cairo		
Telephone Number	26815000	**Fax:** 26815001	
Website	http://www.gsk.com/en-gb/contact-us/worldwide/egypt/		
E-mail	EG.Investor-Relation@GSK.com		

The Investor Relations Manager at the company works to present a comprehensive view of the company's activities and disclose both routine and material events through reports, statements, and forms on the company's website. They also monitor investors and regulatory bodies, providing any necessary clarifications through the following actions:

- Organizing the information issued by the company according to the applicable disclosure rules.
- Regularly participating in investment conferences and meetings in Egypt, and updating information related to new laws and ministerial decisions.
- Consulting with the company's financial management on any matters that require disclosure.
- Enhancing participation on the company's stock exchange page and preparing the required disclosure reports for the company, including maintaining and updating the Investor Relations pages on the company's website.
- Maintaining continuous communication with Misr for Clearing and Settlement to track and update investor data, as well as with the Financial Regulatory Authority to provide the required financial data in accordance with disclosure requirements.

Disclosure Tools

<u>**Annual Report**</u>

- The annual report is issued by Glaxo Group Limited and includes a summary of the Board of Directors' report, the financial statements, and all other information that is relevant to current and potential shareholders, investors, and stakeholders.

Board of Directors Report

The company issues a quarterly Board of Directors report that includes a summary of business results, financial statements, and any additional information. The report contains the following:

- Board of Directors composition
- Business results and financial indicators
- Proposed dividend distributions
- Corporate social responsibility
- Current and future company projects
- Additionally, the company issues an annual Board of Directors report, which is attached to the financial statements and prepared according to the provisions of Article 40 of the Listing Rules.

Disclosure Report

Pursuant to Article 30 of the Listing Rules, the company prepares and discloses quarterly reports outlining any significant events, which are submitted to the relevant regulatory bodies.

Sustainability Report

The company outlines its sustainability-related activities, including its achievements in the economic, environmental, and social fields, within its periodic and annual activity reports.

Charters and Policies

Code of Ethics and Professional Conduct

The company adheres to an internal code of ethics and professional conduct, which includes a set of values that regulate and organize the rules of workplace behavior and professional ethics within the parent company.

Succession Planning Policy

The Human Resources department implements this policy, which aims to create procedures for evaluating the selection, appointment, and promotion processes, ensuring the company secures the best-qualified individuals in the appropriate positions, as practiced by the parent company.

Whistleblowing Policy

The company follows an internal code that encourages employees or stakeholders to report any practices that violate the ethical conduct rules or engage in illegal activities, as implemented by the parent company.

Policy on Transactions with Insiders, Related Parties, and Connected Parties

The company's management regularly reviews transactions and contracts with related parties to ensure that fair pricing is applied and in compliance with the requirements of regulatory authorities.

GSK
GlaxoSmithKline S. A. E
جلاكسو سميثكلاين ش. م. م

Corporate Social and Environmental Responsibility Policy

The company takes its responsibility seriously by participating in various community activities aimed at social development and environmental preservation.

Managing Director
MS. Heba Elmorshdy

GSK
GlaxoSmithKline S. A. E
جلاكسو سميثكلاين ش. م. م
٤٦ أ القطاع الأول - التجمع الخامس - القاهرة الجديدة
السجل التجاري: ٢٠٨٤٠٧ التسجيل الضريبي: ٢٣٨ - ٢٨١ - ١٠٠